Autologous Mesothelin-specific TCR-T Cells
- Generic Name
- Autologous Mesothelin-specific TCR-T Cells
Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
Phase 1
Terminated
- Conditions
- Metastatic Pancreatic Ductal AdenocarcinomaStage IV Pancreatic Cancer AJCC v8
- Interventions
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 9
- Registration Number
- NCT04809766
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath